Table 1.

Comparison of demographics, general clinical characteristics, disease severity measures, and sleep quality scores in subjects with and without study follow-up.

	With ≥6 month study follow-up (n=219)			Without study follow-up (n=82)
Characteristics:	Mean (SD)	Range	N(%)	Mean (SD)	Range	N(%)	p-value
Age (years)	50.7 (14.7)	[18 – 86]		46.0 (15.2)	[19 – 82]		0.016
Male			101 (46.1)			38 (46.3)
Female			118 (53.9)			44 (53.7)	0.972
Race:
White/Caucasian			185 (84.5)			67 (81.9)
African American			11 (5.0)			1 (1.2)
Asian			9 (4.1)			5 (6.1)
NH / PI			--			1 (1.2)
Reported Other			14 (6.4)			7 (8.5)	0.218
Ethnicity:
Hispanic/Latino			11 (5.0)			4 (4.9)	0.959
Nasal polyps			84 (38.4)			23 (28.0)	0.096
Prior sinus surgery			110 (50.2)			43 (52.4)	0.733
Asthma			74 (33.8)			27 (32.9)	0.888
ASA intolerance			20 (9.1)			4 (4.9)	0.338
Current smoker/tobacco use			11 (5.0)			11 (13.4)	0.013
Alcohol consumption			103 (47.0)			44 (53.7)	0.306
Depression (self-report)			36 (16.4)			11 (13.4)	0.520
Allergies			78 (35.6)			26 (31.7)	0.525
Ciliary dysfunction / CF			5 (2.3)			4 (4.9)	0.262
Baseline PSQI total score	9.4 (4.6)	[1 – 21]		9.9 (4.4)	[2 – 21]		0.446
Poor Sleep Quality (>5)			158 (72.1)			65 (79.3)	0.209
Baseline RSDI total score	46.5 (25.0)	[1 – 116]		47.9 (25.2)	[4 – 110]		0.646
Baseline SNOT-22 score	53.2 (19.5)	[11 – 106]		51.7 (22.0)	[0 – 102]		0.564
Baseline PHQ-2 score	1.7 (1.7)	[0 – 6]		1.7 (1.7)	[0 – 6]		0.912
Baseline CT score	12.4 (6.0)	[0 – 24]		10.8 (5.3)	[0 – 24]		0.044
Baseline Endoscopy score	6.1 (3.9)	[0 – 18]		5.9 (3.8)	[0 – 14]		0.590

SD=standard deviation. NH/PI=Native Hawaiian/Pacific Islander. ASA=acetylsalicylic acid. Gr=grams. CF=cystic fibrosis. PSQI=Pittsburgh Sleep Quality Index. SNOT-22=Sinonasal outcome test. PHQ-2=Patient Health Questionnaire. CT=computed tomography. Comparisons were assessed using two-tailed independent sample t-tests and chi-square testing where appropriate.